The estimated Net Worth of William D. Turner is at least $349 Тысяча dollars as of 5 April 2022. Mr. Turner owns over 6,447 units of Sierra Oncology Inc stock worth over $349,022 and over the last 4 years he sold SRRA stock worth over $0. In addition, he makes $0 as Chief Regulatory and Technical Operations Officer at Sierra Oncology Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Turner SRRA stock SEC Form 4 insiders trading
William has made over 5 trades of the Sierra Oncology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 6,447 units of SRRA stock worth $77,686 on 5 April 2022.
The largest trade he's ever made was exercising 10,000 units of Sierra Oncology Inc stock on 7 February 2022 worth over $120,500. On average, William trades about 2,500 units every 7 days since 2020. As of 5 April 2022 he still owns at least 6,347 units of Sierra Oncology Inc stock.
You can see the complete history of Mr. Turner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Turner biography
William D. Turner serves as Chief Regulatory and Technical Operations Officer of the Company. Mr. William Turner has more than 25 years of drug development and drug commercialization experience, leading organizations through all phases of product development including commercial drug process, method and facility validations, all phases of clinical programs, numerous drug application filings and several global approvals. William was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years. Prior to that, he served as Vice President of Regulatory Affairs and Global Quality at Dynavax Technologies Corporation as well as several years in a leadership position at MedImmune (now AstraZeneca). He has significant experience in both small molecule and biologic development and has led teams in many therapeutic areas including vaccinology, oncology, hematology, allergy and respiratory. Mr. Turner holds a degree in Medical Microbiology with a minor in Chemistry from California State University at Long Beach .
What's William Turner's mailing address?
William's mailing address filed with the SEC is C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110, SAN MATEO, CA, 94404.
Insiders trading at Sierra Oncology Inc
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth и James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
What does Sierra Oncology Inc do?
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
What does Sierra Oncology Inc's logo look like?
Complete history of Mr. Turner stock trades at Sierra Oncology Inc
Sierra Oncology Inc executives and stock owners
Sierra Oncology Inc executives and other stock owners filed with the SEC include:
-
Barbara Klencke,
Chief Development Officer -
Mark Kowalski,
Chief Medical Officer -
Sukhi Jagpal,
Chief Financial Officer -
Dr. Stephen George Dilly M.B.B.S, Ph.D.,
Pres, CEO & Director -
Dr. Barbara J. Klencke M.D.,
Chief Medical Officer -
Dr. Mark M. Kowalski M.D., Ph.D.,
Chief of Research & Early Devel. -
Robert Pelzer,
Independent Chairman of the Board -
James Smith,
Vice President Corporate Affairs -
Andrew Sinclair,
Independent Director -
Josh Richardson,
Independent Director -
Jeffrey Cooper,
Independent Director -
Mona Ashiya,
Independent Director -
Andrew Allen,
Independent Director -
Gaurav Aggarwal,
Independent Director -
Craig Collard,
Director -
William Turner,
Chief Regulatory and Technical Operations Officer -
Kevin Norrett,
Chief Business Officer -
Christina Thomson,
General Counsel -
Stephen Dilly,
President, Chief Executive Officer, Director -
Kevin Norrett M.B.A., M.S.,
Chief Bus. Officer -
William D. Turner,
Chief Regulatory & Technical Operations Officer -
Christina Thomson J.D., M.S.,
Gen. Counsel, Chief Compliance Officer & Sec. -
Sukhi Jagpal CA, CPA, CBV, MBA,
Chief Financial Officer -
Daniel Estes,
Director -
James N Topper,
Director -
Nicholas Glover,
CEO and President -
Nicole Onetto,
Director -
Tran Nguyen,
Director -
Donald R Parfet,
Director -
Angie You,
Chief Bus. & Strat. Officer -
Capital Partners Iii, Llc L...,
-
Christian Hassig,
Chief Scientific Officer -
Opportunity, Llc Vivo Oppor...,
-
Advisors Llcorbimed Capital...,
-
Opportunity, Llc Vivo Oppor...,
-
Advisors Llc Orbi Med Capit...,
-
Georgia Erbez,
Director -
Christy J. Oliger,
Director -
Llp Abingworth,
10% owner -
Mary Christina Thomson,
General Counsel -
Advisors Llc Orbi Med Capit...,